Hepatitis B: an important public health issue.

Area of Science:

• Hepatology
• Infectious Diseases
• Virology

Background:

• Hepatitis B virus (HBV) infection is a major global health concern, with 350 million chronic carriers worldwide.
• Prevalence varies significantly by region, impacting disease transmission routes and management strategies.
• Chronic HBV infection can lead to severe liver disease, including cirrhosis and liver cancer.

Purpose of the Study:

• To review the current landscape of chronic Hepatitis B treatment.
• To highlight the limitations of existing therapies like interferon (IFN) alpha.
• To introduce lamivudine as a novel, effective oral treatment option.

Main Methods:

• Review of existing literature on Hepatitis B epidemiology and treatment.
• Comparison of therapeutic outcomes and tolerability of interferon alpha and lamivudine.
• Analysis of lamivudine's impact on managing chronic HBV infection.

Main Results:

• Interferon alpha treatment for chronic Hepatitis B has significant drawbacks, including cost, administration route, and side effects.
• Lamivudine, a nucleoside analogue, is the first effective and well-tolerated oral treatment for chronic Hepatitis B.
• Lamivudine expands therapeutic options for chronic HBV patients.

Conclusions:

• While eradication of Hepatitis B remains a challenge, lamivudine represents a significant advancement in managing chronic HBV-associated liver disease.
• The development of oral therapies like lamivudine is crucial for addressing the global public health burden of Hepatitis B.
• Lamivudine offers improved accessibility and tolerability for a broader patient population.